Skip to main content

Table 5 Effect modification by type 2 diabetes on the association between NGFR genotype and the risk of Alzheimer's disease stratified by ApoE ε4 status

From: Genetic polymorphisms of nerve growth factor receptor (NGFR) and the risk of Alzheimer's disease

 

NGFR non- variant carriers

NGFR variant carriers

P interaction

 

Case/control

OR

Case/control

OR (95%CI)

 

ApoE ε 4 non-carriers

   

   rs2072445

     

Diabetes

25/40

1.00

6/4

5.53 (0.53-57.61)

 

Without diabetes

104/250

1.00

20/35

1.43 (0.70-2.92)

0.16

   rs2072446

     

Diabetes

26/26

1.00

5/18

0.48 (0.12-1.98)

 

Without diabetes

89/227

1.00

35/58

2.18 (1.19-4.00)

0.007*

   rs734194

     

Diabetes

23/23

1.00

8/21

0.28 (0.08-0.98)

 

Without diabetes

62/144

1.00

62/141

0.87 (0.52-1.45)

0.14

   rs741072

     

Diabetes

8/21

1.00

23/23

2.97 (0.91-9.74)

 

Without diabetes

56/113

1.00

68/172

0.85 (0.50-1.43)

0.04

   rs741073

     

Diabetes

14/27

1.00

17/17

1.84 (0.57-5.89)

 

Without diabetes

71/154

1.00

53/131

0.96 (0.57-1.61)

0.39

ApoE ε4 carriers

   

   rs2072445

     

Diabetes

12/5

1.00

4/1

NA

 

Without diabetes

81/38

1.00

10/11

0.49 (0.16-1.46)

NA

   rs2072446

     

Diabetes

13/4

1.00

3/2

NA

 

Without diabetes

79/44

1.00

12/5

1.49 (0.36-6.21)

NA

   rs734194

     

Diabetes

7/3

1.00

9/3

2.55 (0.20-33.18)

 

Without diabetes

52/25

1.00

39/24

0.63 (0.28-1.46)

0.69

   rs741072

     

Diabetes

11/4

1.00

5/2

2.09 (0.15-29.98)

 

Without diabetes

35/19

1.00

56/30

1.13 (0.47-2.69)

0.93

   rs741073

     

Diabetes

8/5

1.00

8/1

NA

 

Without diabetes

51/31

1.00

40/18

1.24 (0.54-2.86)

NA

  1. All models were adjusted for age, sex, and education.
  2. Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.
  3. *Result remained significant after controlling for FDR.